GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MDR-001

Company
MindRank AI Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for MDR-001 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06778850

    A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

    Not yet reported, Not yet reported MindRank AI Ltd 131 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Overweight and Obese Volunteers
    View official trial listing →
  • Not yet recruiting NCT NCT06606483

    A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

    Not yet reported MindRank AI Ltd 300 participants Est. completion 2025-09-30 19 sites Stand-alone
    Other conditions: Obesity, Overweight and Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07110766

    Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

    Not yet reported MindRank AI Ltd 24 participants Est. completion 2025-10-30 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07274137

    A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

    Not yet reported MindRank AI Ltd 738 participants Est. completion 2027-07 45 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07550621

    Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

    Not yet reported MindRank AI Ltd 28 participants Est. completion 2026-06-08 1 site Stand-alone
    Other conditions: Healthy Volunteers (HV)
    View official trial listing →
  • Not yet recruiting NCT NCT07550634

    Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment

    Not yet reported MindRank AI Ltd 32 participants Est. completion 2026-10-30 1 site Stand-alone
    Other conditions: Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.